BACKGROUND: Allopregnanolone (ALLO) is a potent positive modulator of γ-aminobutyric acidA receptors (GABAA Rs) that affects ethanol (EtOH) withdrawal. Finasteride (FIN), a 5α-reductase inhibitor that blocks the formation of ALLO and other GABAergic neurosteroids, alters EtOH sensitivity. Recently, we found that Withdrawal Seizure-Prone mice from the first genetic replicate (WSP-1) exhibited behavioral tolerance to the anticonvulsant effect of intrahippocampal ALLO during EtOH withdrawal and that intrahippocampal FIN significantly increased EtOH withdrawal severity. The purpose of this study was to determine whether neurosteroid manipulations in the substantia nigra reticulata (SNR) and ventral tegmental area (VTA) produced effects during EtOH withdrawal comparable to those seen with intrahippocampal ALLO and FIN. METHODS: Male WSP-1 mice were surgically implanted with bilateral guide cannulae aimed at the SNR or VTA at 2 weeks prior to EtOH vapor or air exposure for 72 hours. Initial studies examined the anticonvulsant effect of a single ALLO infusion (0, 100, or 400 ng/side) at a time corresponding to peak withdrawal in the air- and EtOH-exposed mice. Separate studies examined the effect of 4 FIN infusions (0 or 10 μg/side/d) during the development of physical dependence on the expression of EtOH withdrawal. RESULTS: ALLO infusion exerted a potent anticonvulsant effect in EtOH-naïve mice, but a diminished anticonvulsant effect during EtOH withdrawal. Administration of FIN into the SNR exerted a delayed proconvulsant effect in EtOH-naïve mice, whereas infusion into the VTA increased EtOH withdrawal duration. CONCLUSIONS: Activation of local GABAA Rs in the SNR and VTA via ALLO infusion is sufficient to exert an anticonvulsant effect in naïve mice and to produce behavioral tolerance to the anticonvulsant effect of ALLO infusion during EtOH withdrawal. Thus, EtOH withdrawal reduced sensitivity of GABAA Rs to GABAergic neurosteroids in 2 neuroanatomical substrates within the basal ganglia in WSP-1 male mice.
BACKGROUND:Allopregnanolone (ALLO) is a potent positive modulator of γ-aminobutyric acidA receptors (GABAA Rs) that affects ethanol (EtOH) withdrawal. Finasteride (FIN), a 5α-reductase inhibitor that blocks the formation of ALLO and other GABAergic neurosteroids, alters EtOH sensitivity. Recently, we found that Withdrawal Seizure-Prone mice from the first genetic replicate (WSP-1) exhibited behavioral tolerance to the anticonvulsant effect of intrahippocampal ALLO during EtOH withdrawal and that intrahippocampal FIN significantly increased EtOH withdrawal severity. The purpose of this study was to determine whether neurosteroid manipulations in the substantia nigra reticulata (SNR) and ventral tegmental area (VTA) produced effects during EtOH withdrawal comparable to those seen with intrahippocampal ALLO and FIN. METHODS: Male WSP-1 mice were surgically implanted with bilateral guide cannulae aimed at the SNR or VTA at 2 weeks prior to EtOH vapor or air exposure for 72 hours. Initial studies examined the anticonvulsant effect of a single ALLO infusion (0, 100, or 400 ng/side) at a time corresponding to peak withdrawal in the air- and EtOH-exposed mice. Separate studies examined the effect of 4 FIN infusions (0 or 10 μg/side/d) during the development of physical dependence on the expression of EtOH withdrawal. RESULTS:ALLO infusion exerted a potent anticonvulsant effect in EtOH-naïve mice, but a diminished anticonvulsant effect during EtOH withdrawal. Administration of FIN into the SNR exerted a delayed proconvulsant effect in EtOH-naïve mice, whereas infusion into the VTA increased EtOH withdrawal duration. CONCLUSIONS: Activation of local GABAA Rs in the SNR and VTA via ALLO infusion is sufficient to exert an anticonvulsant effect in naïve mice and to produce behavioral tolerance to the anticonvulsant effect of ALLO infusion during EtOH withdrawal. Thus, EtOH withdrawal reduced sensitivity of GABAA Rs to GABAergic neurosteroids in 2 neuroanatomical substrates within the basal ganglia in WSP-1 male mice.
Authors: Theodora Duka; John Gentry; Robert Malcolm; Tamzin L Ripley; Gilyanna Borlikova; Dai N Stephens; Lynn M Veatch; Howard C Becker; Fulton T Crews Journal: Alcohol Clin Exp Res Date: 2004-02 Impact factor: 3.455
Authors: Deborah A Finn; Amy S Beadles-Bohling; Ethan H Beckley; Matthew M Ford; Katherine R Gililland; Rebecca E Gorin-Meyer; Kristine M Wiren Journal: CNS Drug Rev Date: 2006
Authors: Deborah A Finn; Matthew M Ford; Kristine M Wiren; Charles E Roselli; John C Crabbe Journal: Pharmacol Ther Date: 2004-02 Impact factor: 12.310
Authors: Katherine R Gililland-Kaufman; Michelle A Tanchuck; Matthew M Ford; John C Crabbe; Amy S Beadles-Bohling; Christopher Snelling; Gregory P Mark; Deborah A Finn Journal: Brain Res Date: 2008-09-24 Impact factor: 3.252
Authors: Michelle A Nipper; Jeremiah P Jensen; Melinda L Helms; Matthew M Ford; John C Crabbe; David J Rossi; Deborah A Finn Journal: Neuroscience Date: 2018-12-02 Impact factor: 3.590
Authors: Antoniette M Maldonado-Devincci; Jason B Cook; Todd K O'Buckley; Danielle H Morrow; Raechel E McKinley; Marcelo F Lopez; Howard C Becker; A Leslie Morrow Journal: Alcohol Clin Exp Res Date: 2014-10-07 Impact factor: 3.455
Authors: Michelle A Tanchuck-Nipper; Matthew M Ford; Anna Hertzberg; Amy Beadles-Bohling; Debra K Cozzoli; Deborah A Finn Journal: Behav Genet Date: 2014-10-31 Impact factor: 2.805
Authors: Christopher Snelling; Michelle A Tanchuck-Nipper; Matthew M Ford; Jeremiah P Jensen; Debra K Cozzoli; Marcia J Ramaker; Melinda Helms; John C Crabbe; David J Rossi; Deborah A Finn Journal: Psychopharmacology (Berl) Date: 2014-05-29 Impact factor: 4.530